The summer heat is on, but it's not just the temperatures blazing - a handful of red hot stocks are setting the Street aflame with Wall Street's top analysts pounding the table. From innovative biotechs to consumer staple stalwarts, this eclectic group spans nearly every sector as bullish calls reverberate with robust upside projections. It's a prime opportunity to capitalize on accelerating momentum before share prices potentially race higher.
Leading the charge is PTC Therapeutics (PTCT), the genetic disorder drug pioneer garnering a $47 average price target that implies nearly 50% upside from current levels. While Morgan Stanley's Jeffrey Hung is in wait-and-see mode with a "Hold" stance, the biotech's proprietary pipeline treating rare diseases commands respect. PTCT's RNA therapies tackling muscular dystrophies and cystic fibrosis are potential blockbusters markets have yet to fully appreciate.
Celsius Holdings (CELH) is sizzling after UBS' Peter Grom reaffirmed his "Buy" rating and $70 price target on the energy drink disruptor. With a $65.75 consensus price target suggesting 27% upside, CELH's focus on healthy functional beverages carves an attractive niche amidst consumer wellness crazes. Despite recent share price declines, its combination of growth and cash flow resilience position it as a compelling consumer defensive play.
Train titan Canadian National Railway (CNI) remains an analyst darling, with TD Securities' Cherilyn Radbourne among those espousing a constructive $135.58 target. Rails boast powerful oligopoly dynamics, with CNI's continent-spanning network generating consistently robust free cash flows. While cyclical risks linger, the stock's 3.6% yield and decade-plus dividend growth streak foster plenty of admiration.
The pandemic consumed Domino's Pizza (DPZ), but now Oppenheimer's Brian Bittner is betting big on its comps-driven revival with a daring "Buy" rating and $580 price objective. If achieved, that implies over 40% upside for the $37 billion pizza delivery juggernaut as digital ordering platforms, operational improvements, and value positioning fuel renewed momentum. DPZ is a prime turnaround story regaining sizzle.
Hope Is Not a Strategy! No matter the outcome of the election, the playbooks on both sides are clear - death sentence for your wealth? Learn more |
Nurix Therapeutics (NRIX) may be a small-cap biotech, but its $27.60 consensus price target signals nearly 100% upside potential from here. RBC's Gregory Renza is particularly bullish on its drug pipeline premised on restoring protein homeostasis to treat cancer and immune-inflammatory diseases. The recently initiated Phase 1 study for NX-2127 could be an upside catalyst if early data proves positive.
For a mega-cap tech anchor, analysts are salivating over Oracle (ORCL)'s cloud growth trajectory under Safra Catz's leadership. Piper Sandler's Brent Bracelin has a "Buy" and $150 target on shares, implying over 20% gains as ORCL rides accelerating cloud adoption. With operating margins nearing 40%, prodigious cash flows augur well for continued shareholder rewards including buybacks and dividend increases.
While Conagra Brands (CAG) isn't glamorous, Evercore ISI's David Palmer has a contrarian "Hold" call on the $30.20 consensus target. The consumer staples play has struggled with inflation overhang and brand renovation, but disciplined cost-cutting positions it for improved pricing power. Any signs of emerging margin leverage could prompt earnings surprises reigniting bullish revaluations.
Last but not least is Delta Air Lines (DAL), where Barclays' Brandon Oglenski initiated coverage with an exuberant "Buy" rating and $52 price target implying nearly 20% upside. The reopening narrative remains firmly intact despite industry turbulence, as DAL gains traction with premium leisure segments. Relatively modest fuel hedging compared to peers could amplify operating earnings tailwinds from any pricing retreats.
This diverse slate of compelling opportunities cuts across highly disparate segments, reflecting just how pervasive fundamental upside could be gestating. Innovative biotech disruptors, economically-resilient consumer plays, logistics moats, potential turnaround stories, and post-COVID travel renaissances collectively harmonize into a very bullish chorus.
Some consistent threads unite the most ardent buy calls - pricing power erosion creating discounted cash flow disconnects, defensive business models deflecting macro headwinds, niche exposure to accelerating demand shifts shaping entire verticals. In many cases, disciplined capital allocation towards shareholders underpins the upbeat thesis, whether via buybacks, consistent dividends, or well-timed bolt-on M&A.
Sponsor |
The original “Magnificent Seven” stocks generated 16,800% over the last 20 years.
But now a new set of AI stocks is set to take over. Full Story >> |
Perhaps most critically, many already display positive price momentum and improving technical patterns. So on top of robust fundamentals and valuation backstops, these names possess the quintessential characteristicsephemeral traders crave. It's the "sirloin" opportunity serving both fundamental and quantitative appetites.
At the end of the day, resonating buy-side endorsements carry incredible significance when battling cross-currents of persistent inflation and looming growth concerns. While ratings aim to assist investors navigating complex environments, extreme upside conviction represents the highest form of confidence analysts can bestow. PTCT, CELH, CNI, DPZ, NRIX, ORCL, CAG, and DAL have all received that affirmation in spades.
So when temperatures peak in July's sweltering doldrums, count these eight momentum plays among the Street's most respected sizzlers. With robust upside potential backing their rallying cries, opportunistic investors stand to prosper by heeding Wall Street's red hot buy alerts. From small-cap innovators to blue-chip dividend growers, few stones are being left unturned in pursuit of alpha generation this summer.